Biotech company Innervace — a spin-out from the University of Pennsylvania — has raised up to $40 million to support the development of its novel regenerative cell therapy platform for Parkinson’s disease. Innervace’s cell therapy
A protein “traffic jam” inside nerve cells promotes the buildup of shorter and toxic tau — a protein that forms toxic aggregates in Parkinson’s and other neurodegenerative disorders — according to a new study using fruit
AC Immune will use a new $500,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the development of its ACI-12589 positron emission tomography (PET) scan tracer for the detection of
SynAgile announced the full enrollment of a Phase 2 clinical trial evaluating DopaFuse, its noninvasive system for the continuous oral delivery of levodopa/carbidopa to people with Parkinson’s disease. Sixteen adults being treated with levodopa/carbidopa (LD/CD) in a tablet
Amneal Pharmaceuticals is seeking U.S. approval of IPX-203, its extended-release carbidopa-levodopa (CD/LD) tablets, for Parkinson’s disease. The company submitted an Investigational New Drug Application to the Food and Drug Administration (FDA), which is based on